Torsten Malmström
Vermögen: 2 Mio $ am 31.05.2026
Vermögen: 2 Mio $ am 31.05.2026
Torsten Malmström formerly worked at Zealand Pharma A, as Director-Pharmaceutical Development, PolyPeptide Laboratories (Sweden) AB, as Development Director, AstraZeneca AB, as Team Manager, and Camurus AB, as Vice President-Technical Operations.
Dr. Malmström received his doctorate degree from the University of Lund.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CAMURUS AB 0,06 % | 31.12.2024 | 35 363 ( 0,06 % ) | 2 Mio $ | 31.05.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services Researches and develops pharmaceutical products | Corporate Officer/Principal | - |
PolyPeptide Laboratories (Sweden) AB
PolyPeptide Laboratories (Sweden) AB BiotechnologyHealth Technology Manufactures polypeptide, custom peptide synthesis, peptide synthesis and generic peptides | Corporate Officer/Principal | - |
| ZEALAND PHARMA A/S | Corporate Officer/Principal | - |
| CAMURUS AB | Technik-/Wissenschafts-/F&E-Leiter | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 5 |
|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services Researches and develops pharmaceutical products | Commercial Services |
Zealand Pharma A/S
Zealand Pharma A/S BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops peptide based medicines | Health Technology |
Camurus AB
Camurus AB Pharmaceuticals: MajorHealth Technology Provides nanoscale drug delivery systems for development of high value therapeutics | Health Technology |
University of Lund
University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PolyPeptide Laboratories (Sweden) AB
PolyPeptide Laboratories (Sweden) AB BiotechnologyHealth Technology Manufactures polypeptide, custom peptide synthesis, peptide synthesis and generic peptides | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen